ORIC analyst estimates
Oric (ORIC) analyst ratings, the average price target and its range, and every firm's latest call.
ORIC analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 27, 2026 | Wedbush | Oric Pharmaceuticals price target lowered to $14 from $17 at Wedbush | $14.00 |
| Oct 26, 2026 | Stifel Nicolaus | Oric Pharmaceuticals price target raised to $18 from $14 at Stifel | $18.00 |
| Oct 5, 2026 | Leerink Partners | Oric Pharmaceuticals initiated with an Outperform at Leerink | $26.00 |
| Sep 23, 2026 | BTIG | Oric Pharmaceuticals initiated with a Buy at BTIG | $26.00 |
| Aug 10, 2026 | H.C. Wainwright | Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright | $27.00 |
| May 15, 2026 | Goldman Sachs | Oric Pharmaceuticals moved to Buy rating at Goldman Sachs | $15.00 |
| Feb 24, 2026 | Oppenheimer | Oppenheimer Reiterates Outperform Rating on ORIC Pharmaceuticals (ORIC) | $15.00 |
| Feb 24, 2026 | H.C. Wainwright | Oric Pharmaceuticals price target raised to $25 from $23 at H.C. Wainwright | $25.00 |
| Jan 7, 2026 | Piper Sandler | Oric Pharmaceuticals initiated with an Overweight at Piper Sandler | $22.00 |
| Dec 8, 2025 | Wells Fargo | Oric Pharmaceuticals price target raised to $25 from $19 at Wells Fargo | $25.00 |
| Nov 14, 2025 | H.C. Wainwright | Oric Pharmaceuticals price target raised to $23 from $19 at H.C. Wainwright | $23.00 |
| Sep 4, 2025 | Guggenheim | Oric Pharmaceuticals assumed with a Buy at Guggenheim | $18.00 |
| May 6, 2025 | Oppenheimer | Oric Pharmaceuticals price target lowered to $12 from $15 at Oppenheimer | $12.00 |
| Sep 5, 2024 | Stifel Nicolaus | Oric Pharmaceuticals initiated with a Buy at Stifel | $20.00 |
| Mar 21, 2024 | H.C. Wainwright | ORIC Pharamceuticals (ORIC) PT Raised to $21 at H.C. Wainwright following 2023 results | $21.00 |
- 12 firms rate ORIC: 11 buy, 1 hold, 0 sell.
- The average price target is $21.00 from 6 analysts, from $14.00 to $27.00.
Updated 2026-11-03 11:30 UTC